Loading market dashboard
Central Securities Corp.
CETFinancial ServicesAMEXUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
NEW YORK--(BUSINESS WIRE)--The Board of Directors of Central Securities Corporation (NYSE American: CET), a closed-end investment company, today declared the following dividend: Class of Stock Rate Ex- and Record Date Payment Date Common Stock $0.31 6/12/2026 6/26/2026 Of the $0.31 per share to be paid on June 26, 2026, $0.06 is expected to be taxable as ordinary income and $0.25 is expected to be taxable as long-term capital gain. The final tax breakdown of all amounts paid during 2026.
STOCKHOLM, May 13, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's first quarter report for January - March 2026 on Wednesday, May 20, 2026, at 8:00 a.m. CET. In conjunction with the report, BioArctic invites investors, analysts and media to a webcast (in English) on May 20, at 9:30 a.m CET, where Gunilla Osswald, CEO, and Anders Martin-Löf, CFO, together with colleagues, will present and comment on the first quarter report, followed by a Q&A session.
Galapagos' name change to Lakefront Biotherapeutics approved at the Company's EGM (Euronext & NASDAQ: LKFT) Collaboration Agreement with Gilead to advance potential First and Best-in-Class T Cell Engager expected to close in the Second Quarter of 2026 Following this transaction, including estimated associated R&D spend until first approval, the Company will continue to have a majority of its current cash remaining for additional strategic transactions and other capital allocation priorities Year-end 2026 cash and financial investments balance expected to be approximately €2B Management to host conference call on May 7, 2026, at 14:00 CET / 8:00 am ET Mechelen, Belgium ; May 6, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today reported its financial results for the first quarter of 2026 and provided a business update. “Having joined the company just one year ago, I'm thrilled with our progress. I am looking forward to consummating our partnership with Gilead and adding Ouro Medicines' talented team and its portfolio of programs to our Company, including the potential first and best in class T cell engager in autoimmune diseases, gamgertamig (OM336). We are excited that our Company is rebranding as Lakefront Biotherapeutics as this name reflects our Company's strategic evolution,” said Henry Gosebruch, Chief Executive Officer of Galapagos. Aaron Cox, Chief Financial Officer of Galapagos, added, “Following the anticipated use of cash to fund our collaboration with Gilead concerning its acquisition of Ouro Medicines, the Company will remain robustly capitalized and will have increased flexibility, including the ability to spend up to $500 million for business development independent of Gilead and not subject to our 2019 Option, License, and Collaboration Agreement with Gilead. This would also include the potential to use up to $150 million of that $500 million for share repurchases to the extent that we have available distributable reserves. In addition to the upfront consideration of $837.5 million, we anticipate additional 2026 Ouro-related cash expenditures to be in the range of €60-75 million, inclusive of R&D costs, one-time transaction costs and assuming a mid-year closing of the transaction.” First Quarter 2026 Business Update
Press Release – No. 8 / 2026 Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results Copenhagen, Denmark and Boston, Massachusetts, April 30, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
NEW YORK--(BUSINESS WIRE)--Central Securities Corporation (NYSE American: CET), a closed-end investment company, today released its Report to Stockholders for the three months ended March 31, 2026. Figures as of March 31, 2026 compared with those of one year ago, are as follows: March 31, March 31, 2026 2025 Net assets per common share $58.94 $54.46 Net assets $1,741,512,380 $1,575,432,513 Shares outstanding 29,549,265 28,927,937 Additional details are available at www.cen.
BNP PARIBAS CONFIRMS ITS CET1 RATIO TRAJECTORY FOLLOWING THE UPDATE OF THE ECB O-SII FRAMEWORK PRESS RELEASE Paris, 28th April 2026 On the 20th December 2024, the European Central Bank (ECB) published an updated framework for the assessment of capital buffer requirements applicable to Other Systemically Important Institutions (O-SIIs). On the 28th April 2026, the ECB released the O-SII scores under this framework.
Paris, France – April 28, 2026 Q1 2026 financial results and conference call Viridien will publish its first quarter 2026 results on Tuesday, May 5, after market close. The press release and presentation will be made available on www.viridiengroup.com at 5.45 pm (CET) An English-language conference call is scheduled at 6.00 pm (CET) on the same day Participants must register for the conference call by clicking here to receive a dial-in number and PIN code.
STOCKHOLM, April 27, 2026 /PRNewswire/ -- Truecaller, the leading global platform for safe and trusted communication is publishing its interim report for January-March 2026 on Thursday 7 th of May 2026 at 07.30 CET. Rishit Jhunjhunwala, CEO and Odd Bolin, CFO presents the report and answers questions in a webcast and conference call at 13.00 CET the same day.
COFACE SA: Combined Shareholders' Meeting on Tuesday, May 19, 2026 at 2:00 p.m. CET Paris, April 9, 2026 – 5:45 p.m.
New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company will continue to have a majority of its cash remaining for additional strategic transactions and other capital allocation priorities Opportunity to develop a potential first-in-class & best-in-class T cell engager in autoimmune diseases with gamgertamig Management to host conference call today, March 31, 2026, at 14:00 CET / 8:00 am ET Mechelen, Belgium; March 31, 2026, 7.30 CET; regulated information – Announcement in application of Article 7:97, §4/1 of the BCCA — Galapagos NV (Euronext & NASDAQ: GLPG) (“Galapagos” or the “Company”) today announced that it has entered into a binding agreement (the "Framework Agreement") with Gilead Sciences, Inc. ("Gilead") in connection with Gilead's definitive agreement to acquire all of the outstanding equity interests of US-based Ouro Medicines, LLC ("Ouro"), a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases. Gamgertamig (OM336) is a clinical‑stage BCMAxCD3 T cell engager designed to enable rapid and deep plasma and B‑cell depletion following a short duration, subcutaneously administered treatment course.
Mechelen, Belgium; March 26, 2026, 21:01 CET; regulated information — Galapagos NV (Euronext & NASDAQ: GLPG) today published its annual report for the financial year 2025 and announced that its Annual Shareholders' Meeting (AGM) and an Extraordinary Shareholders' Meeting (EGM) will be held sequentially on Tuesday, April 28, 2026 at 14:00 CET and 15:00 CET at Schaliënhoevedreef 20T, 2800 Mechelen, Belgium.
LUND, Sweden, March 24, 2026 /PRNewswire/ -- Alfa Laval will release first quarter earnings on 22 April at 13:00 pm CET. The conference call will start at 14:00 pm CET.
Correction of the publication from 20. Mar 2026/ 09:15 CET/CEST - Deutsche Lufthansa AG: Mr Carsten Spohr, Acquisition
